Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Akebia Therapeutics (AKBA) Receivables - Other (2016 - 2026)

Akebia Therapeutics has reported Receivables - Other over the past 10 years, most recently at $500000.0 for Q4 2025.

  • Quarterly Receivables - Other fell 75.12% to $500000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $500000.0 through Dec 2025, down 75.12% year-over-year, with the annual reading at $500000.0 for FY2025, 75.12% down from the prior year.
  • Receivables - Other was $500000.0 for Q4 2025 at Akebia Therapeutics, down from $1.2 million in the prior quarter.
  • Over five years, Receivables - Other peaked at $56.6 million in Q2 2022 and troughed at $500000.0 in Q4 2025.
  • The 5-year median for Receivables - Other is $2.7 million (2024), against an average of $7.3 million.
  • Year-over-year, Receivables - Other plummeted 97.73% in 2021 and then skyrocketed 1910.15% in 2022.
  • A 5-year view of Receivables - Other shows it stood at $19.1 million in 2021, then plummeted by 90.04% to $1.9 million in 2022, then soared by 75.33% to $3.3 million in 2023, then tumbled by 39.69% to $2.0 million in 2024, then plummeted by 75.12% to $500000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Receivables - Other are $500000.0 (Q4 2025), $1.2 million (Q1 2025), and $2.0 million (Q4 2024).